On June 15, 2020, Knowledge Ecology International (KEI) and the Union for Affordable Cancer Treatments (UACT) submitted joint comments to the National Institutes of Health regarding two prospective exclusive patent licenses: “Prospective Grant of an Exclusive Patent License: Development and… Continue Reading
Update: The NIH sent a response to our comments, available here. The response fails to address the glaring lack of information available regarding Retargeted Therapeutics. On June 8, 2020, Knowledge Ecology International and the Union for Affordable Cancer Treatment (UACT)… Continue Reading
On June 3, 2020, the U.S. Government Accountability Office (GAO) sent KEI four questions about the transparency of the intellectual property HHS owns and how HHS manages those rights. On June 22, 2020, we sent this response. KEI response to… Continue Reading
Other Transaction Agreements: Government Contracts that May Eliminate Protections for the Public on Pricing, Access and Competition, Including in Connection with COVID-19 KEI Briefing Note 2020:3 June 29, 2020 (revision of June 24 version) Kathryn Ardizzone James Love The most… Continue Reading
KEI Research Note 2020:2 Role of Private Sector, Governments and Charities in Funding Research and Development Related to Tocilizumab Luis Gil Abinader, May 28, 2020. From the Introduction: The funding of R&D for tocilizumab can be described as having three… Continue Reading
On Tuesday April 28, 2020, KEI submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: AAV Mediated Exendin-4 Gene Transfer to Salivary Glands To Protect Subjects From Diabetes or Obesity” (85… Continue Reading
On Friday April 17, 2020, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: The Development of Bispecific Antibodies Targeting Glypican 1 (GPC1) for the Treatment of… Continue Reading
On Friday April 17, 2020, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Methods and Compositions for Adoptive Cell Therapy” to Lyell Immunopharma, Inc. (85 FR… Continue Reading
On April 6, 2020, KEI received a response from the National Institutes of Health (NIH) to a letter we sent to DHHS Secretary Alex Azar on March 13, 2020 regarding three areas in Section 202 of the Bayh-Dole Act that… Continue Reading